ENVISION HLTHCR Stock Analysis, Valuation (NYSE:EVHC)

Add to My Stocks
$50.21 $0.33 (0.66%) EVHC stock closing price Aug 18, 2017 (Closing)
Watch Robo Advisor Video of EVHC Stock Analysis
ENVISION HLTHCR
Updated on : Aug 18, 2017
previous close
EVHC 50.2 (0%)
S&P 500 2425.6 (0%)
Closing Price On: Aug 18, 2017
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Medical-Outpatient-Home care
Sector :
Medical
5 Quarter Revenue
Revenue Growth
2017-Q2
$million
%
YOY GROWTH
Compared to the industry
Operating Profit
Operating Margin:
6.4%
Sector Average:
-2.2%
5 Quarter Net Profit
Net Margins
2017-Q2
%
LTM Margin
Debt/Equity Ratio
Debt:
6.33B
Debt/Equity Ratio:
 0.9
Compared to the industry
Cash Flow
Operating cash flow:
$280.6M
Net Income:
$56.3M
PROS      CONS
Recent Growth
Operating Margins
Cash Flow
ROIC
FCF Margin
PE Valuation
Net Margins
High Debt Burden
ROE
Rating: ★★★★★★★★★★ (0/5)
Relative Valuation
EVHC PS :
0.9
Industry PS :
5
Sector:   Medical.   *PE adjusted for one time items.
Other Metrics
Return on Invested Capital:
2.7%
Return on Equity:
-8.9%
Free Cash Flow Margin:
11.8%
Double Tap To Exit Full Screen
0:00
/

ENVISION HLTHCR Analysis Video

137 5 2

View ENVISION HLTHCR stock analysis video. This is our EVHC analyst opinion covering the buy and sell arguments for EVHC stock.

ENVISION HLTHCR Stock Rating (3.3/5)

Our ENVISION HLTHCR stock opinion is based on fundamentals of the company. This ENVISION HLTHCR stock analysis is based on latest 2017 Q2 earnings. The stock price analysis takes into account the company's valuation metrics.

Should you buy EVHC stock?

  • ENVISION HLTHCR's revenue growth came in at 156.7% in 2017 Q2.
  • The TTM operating margin was good at 6.4% for ENVISION HLTHCR.
  • The operating cash flow looks good at 5 times the net income.
  • EVHC stock is trading at an earnings multiple of 13.9 which is better than the industry average of 22.8.
  • The lower PS ratio 0.9 for EVHC stock versus Medical-Outpatient-Home care industry average of 5 is a positive for the company.
  • ENVISION HLTHCR generates a high return on invested capital of 2.7%.
  • The company has a good Free Cash Flow (FCF) margin of 11.8%.

Should you sell EVHC stock?

  • ENVISION HLTHCR posted an average Net loss of -7.4% in the last twelve months.
  • With a debt/equity ratio of  0.9, ENVISION HLTHCR is highly leveraged in comparison to Medical peers.
  • ENVISION HLTHCR has a negative ROE (Return On Equity) of -8.9%, indicating the company is not profitable.

Comments on this video and ENVISION HLTHCR stock